-
Benzinga's Top Pre-Market NASDAQ Losers (QCOR, CAGC, NVDA, CTSH)
Monday, February 7, 2011 - 9:26am | 120Questcor Pharmaceuticals Inc (NASDAQ: QCOR) dipped 4.71% to $14.78 in the pre-market session. QCOR is scheduled to report Q4 and full year 2010 earnings on February 23. China Agritech Inc (NASDAQ: CAGC) lost 2.40% to $9.75 in the pre-market session. CAGC's trailing-twelve-month ROE is 6.23%. NVIDIA...
-
Benzinga's Top Pre-Market NASDAQ Gainers (OREX, PGNX, GOLD, GENZ)
Monday, February 7, 2011 - 9:18am | 164Orexigen Therapeutics Inc (NASDAQ: OREX) rose 5.41% to $3.80 in the pre-market session. OREX shares have dropped 41.11% over the past 52 weeks, while the S&P 500 index has gained 22.95% in the same period. Progenics Pharmaceuticals Inc (NASDAQ: PGNX) added 4.17% to $6 in the pre-market session...
-
Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin
Monday, February 7, 2011 - 9:10am | 155Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) and Astellas Pharma Europe Ltd. announced today the signing of an exclusive collaboration and license agreement to develop and commercialize fidaxomicin, an investigational antibiotic for CDI, in Europe and certain other countries in the Middle East,...
-
Trading Halted: Optimer Pharmaceuticals, News Pending (OPTR)
Monday, February 7, 2011 - 8:57am | 17Optimer Pharmaceuticals (NASDAQ: OPTR) trading is halted, news pending.
-
Cowen Ups BMY To Outperform
Monday, February 7, 2011 - 7:51am | 42Analysts at Cowen upgrade Bristol Myers Squibb Co (NYSE: BMY) from “neutral” to “outperform.” BMY shares gained 0.78% to close at $25.70 on Friday. More Analyst Ratings here
-
Sanofi, Genzyme Closer To $74-A-Share Deal
Saturday, February 5, 2011 - 11:03pm | 266French pharma giant Sanofi-Aventis (NYSE: SNY) and Genzyme (Nasdaq: GENZ), the maker of treatments for genetic disorders, are reportedly close to ending takeover drama that has spanned more than six months as the boards of the two companies are close to agreeing to $74 a share takeover price. The...
-
Calls Purchased on Elan Corporation (ELN)
Friday, February 4, 2011 - 2:28pm | 117Shares of Elan Corporation (NYSE: ELN) are higher on the session by 2.78%, currently trading at $6.66. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name today. A short...
-
Vanda Pharmaceuticals Falling On Disappointing Drug Sales (VNDA)
Friday, February 4, 2011 - 1:21pm | 100According to Adam Feuerstein at theStreet.com, Vanda Pharmaceuticals' (NASDAQ: VNDA) first year sales of a schizophrenia drug Fanapt developed by VNDA and sold by Novartis (NYSE: NVS) totaled just $31.4 million, well below analysts' expectations. According to Feuerstein, that number is high...
-
UBS Price Target Research Summary
Friday, February 4, 2011 - 11:31am | 231UBS is out with a research report this morning regarding its Ratings and Price Target changes. In the report, UBS lowered its AutoNation (NYSE: AN) price target to $27 from $20, lowered its CVS Caremark (NYSE: CVS) price target to $42 from $46, raised Diamond Offshore Drilling's (NYSE: DO) price...
-
Repros Therapeutics Announces Prices Public Offering of Common Stock at $17.15 per Share
Thursday, February 3, 2011 - 4:46pm | 155Repros Therapeutics Inc. (Nasdaq: RPRX) today announced the pricing of its public offering of 690,000 units, consisting of 2,760,000 shares of its common stock, Series A Warrants to purchase 2,070,000 shares of common stock and Series B Warrants to purchase 1,690,500 shares of its common stock, at...
-
Merck Beats but Guides Lower - Analyst Blog
Thursday, February 3, 2011 - 2:31pm | 697Merck & Co.'s (MRK) earnings per share (excluding certain special items) for the fourth quarter of 2010 came in at 88 cents, 5 cents above the Zacks Consensus Estimate and 9 cents above the year-ago earnings. However, including adjustments, the company suffered a loss of 17 cents, well below...
-
Merck Beats but Guides Lower - Analyst Blog
Thursday, February 3, 2011 - 1:48pm | 697Merck & Co.'s (MRK) earnings per share (excluding certain special items) for the fourth quarter of 2010 came in at 88 cents, 5 cents above the Zacks Consensus Estimate and 9 cents above the year-ago earnings. However, including adjustments, the company suffered a loss of 17 cents, well below...
-
NASDAQ Stocks Hitting 52-Week Highs (OTEX, DEPO, SGI, CELL)
Thursday, February 3, 2011 - 11:39am | 160Open Text Corporation (NASDAQ: OTEX) shares gained 12.97% to create a new 52-week high of $57.39. Analysts at RBC Capital upgraded OTEX from "sector perform" to "outperform.” OTEX announced its plans to buy Metastorm for $182 million. Depomed Inc (NASDAQ: DEPO) shares gained 6.86% to create a new...
-
Roche Misses on Tamiflu Decline - Analyst Blog
Thursday, February 3, 2011 - 9:31am | 796Roche Holdings Ltd.'s (RHHBY) earnings increased 7.81% to $3.07 per share for the fiscal year 2010, but fell short of the Zacks Consensus Estimate of $3.22. However, revenues for the year declined 0.8% to $45,642 million and even missed the Zacks Consensus Estimate of $47,844 million. Despite...
-
Roche Misses on Tamiflu Decline - Analyst Blog
Thursday, February 3, 2011 - 9:15am | 796Roche Holdings Ltd.'s (RHHBY) earnings increased 7.81% to $3.07 per share for the fiscal year 2010, but fell short of the Zacks Consensus Estimate of $3.22. However, revenues for the year declined 0.8% to $45,642 million and even missed the Zacks Consensus Estimate of $47,844 million. Despite...